コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ne against human parainfluenza virus type 3 (HPIV3).
2 (NDV), and human parainfluenza virus type 3 (HPIV3).
3 l vaccine for protection against human PIV3 (hPIV3).
4 protein of human parainfluenza virus type 3 (HPIV3).
5 o confer bivalent protection against RSV and HPIV3.
6 l genomes and all 13 samples had >1 read for HPIV3.
7 enes in the promoter proximal position of rB/HPIV3.
8 ced a robust immune response to both RSV and HPIV3.
9 re lower respiratory tract disease caused by HPIV3.
10 ndidate to protect against illness caused by HPIV3.
11 were protected from challenge with wild-type HPIV3.
12 e a bivalent mucosal vaccine against RSV and HPIV3.
13 tablish an effective antiviral state against HPIV3.
14 ble from that conferred by immunization with HPIV3.
15 e genes of bPIV3 were replaced with those of hPIV3.
16 induced by previous infection with wild-type HPIV3.
17 cted hamsters completely upon challenge with hPIV3.
18 play an important role in the replication of HPIV3.
19 was increased for the mutants compared to wt HPIV3.
20 opment as a bivalent vaccine against RSV and HPIV3.
21 izing antibodies in hamsters against RSV and HPIV3.
22 haps other paramyxoviruses, such as hRSV and hPIV3.
23 ed by antibodies to EV than by antibodies to HPIV3.
25 ive by RT-PCR, including 66 HRSV, 2 HPIV2, 5 HPIV3, 3 influenza A virus, and 10 influenza B virus spe
26 yxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of lower respiratory tract disease
28 bovine/human parainfluenza virus type 3 (rB/HPIV3), a recombinant bovine PIV3 (rBPIV3) in which the
29 attenuated recombinant bovine/human PIV3 (rB/HPIV3), a recombinant BPIV3 in which the bovine HN and F
30 of nonhuman primates compared to human PIV3 (HPIV3), an important pathogen of infants and young child
31 phosphorylated forms of GAPDH associate with HPIV3 and are involved in the regulation of virus gene e
32 IV3-F(H)HN(H) as a vaccine candidate against HPIV3 and as a vector for other viral antigens is discus
33 glycoprotein substitution on replication of HPIV3 and BPIV3 in the upper and lower respiratory tract
34 grew to titers comparable to those of their HPIV3 and BPIV3 parents in LLC-MK2 monkey kidney and Mad
37 ee-dimensional structural information on the HPIV3 and NDV HNs, we propose mechanisms for the observe
38 asal route, a route that has been shown with HPIV3 and respiratory syncytial virus vaccines to be rel
40 iently in cells simultaneously infected with HPIV3 and treated with IFN-gamma, indicating that the in
42 ng RNAs of human parainfluenza virus type 3 (HPIV3) and packaging of these proteins within purified v
43 ne against human parainfluenza virus type 3 (HPIV3) and respiratory syncytial virus (RSV) subgroups A
44 ompared to human parainfluenza virus type 3 (HPIV3), and the Ka strain also was shown to be attenuate
45 was similar to that of their parent virus rB/HPIV3, and each of the chimeras induced a robust immune
46 A synthetase had no antiviral effect against HPIV3; and (iii) primary transcription occurred in the a
47 on resulted in only modest decreases in anti-HPIV3 antibodies in sera and was sufficient to confer co
51 atric clinical evaluation.IMPORTANCE RSV and HPIV3 are the first and second leading viral causes of s
52 (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric respiratory pathogens that la
53 (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agents of acute pediatric bronchi
54 hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for the majority of pediatric res
55 (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and second leading viral agents of
56 (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes of pediatric pneumonia and b
62 correlated with the greater potential of the HPIV3 C peptide to interact with the HeV F N peptide coi
63 n paramyxoviruses, including hRSV, hMPV, and hPIV3, cause the majority of acute upper and lower respi
65 ric viruses induced a level of resistance to HPIV3 challenge in these animals which was indistinguish
68 tenuation, and immunogenicity of these BPIV3/HPIV3 chimeras suggest that the modified Jennerian appro
69 llular proteins potentially interacting with HPIV3 cis-acting regulatory RNAs, a gel mobility shift a
70 ecombinant human parainfluenza type 3 virus (HPIV3) containing BPIV3 F and HN glycoprotein genes in p
71 romoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis-elements controlling transc
73 the F and HN genes were replaced with their HPIV3 counterparts, was used to express the major protec
74 common attenuated backbone, specifically rB/HPIV3 derivatives expressing the G and/or F major protec
75 Because immunization for the prevention of HPIV3 disease must occur in early infancy when maternal
77 gle intranasal inoculation of 10(5.3) PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs o
78 Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG,
83 e EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP)
84 us macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intram
85 cinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan
86 inoculation of 10(5.3) PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet d
90 recombinant consisting of BPIV3 bearing the HPIV3 F and HN genes (rBPIV3-F(H)HN(H)) were generated t
91 -neuraminidase (HN), suggesting that NDV and HPIV3 F have stricter requirements for homotypic HN for
92 amyxovirus F or HN glycoproteins with either HPIV3 F or HN does not result in the formation of syncyt
94 further studies were performed with a mutant HPIV3 F protein (F-KDEL) lacking a transmembrane anchor
95 A mutations cause SV5 WR F, but not NDV F or HPIV3 F, to be triggered to cause fusion in the absence
97 N(P-M) virus was attenuated compared to rSeV-HPIV3(F-HN) in LLC-MK2 cells, and yet both vaccine candi
98 accine candidates rSeV-HPIV3HN(P-M) and rSeV-HPIV3(F-HN) were constructed in which the HPIV3 HN open
99 reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhibits infection mediated
100 ereas the virus expressing the RSV F ORF (rB/HPIV3-F1) was eightfold restricted compared to its rB/HP
101 mmunization of hamsters with rB/HPIV3-G1, rB/HPIV3-F1, or a combination of both viruses resulted in a
103 rus type 3 (PIV3) expressing the human PIV3 (hPIV3) fusion (F) and hemagglutinin-neuraminidase (HN) p
104 ecombinant PIV3 expressing the RSV G ORF (rB/HPIV3-G1) was not restricted in its replication in vitro
108 ignals and inserted individually into the rB/HPIV3 genome in the promoter-proximal position preceding
110 lustering revealed the presence of identical HPIV3 genomic sequence in the two of the cases with hosp
111 We show that the molecular determinants for HPIV3 growth in vitro are fundamentally different from t
112 attenuated ones, developed higher levels of HPIV3 hemagglutination-inhibiting serum antibodies than
113 th measles virus (neutralizing antibody) and HPIV3 (hemagglutination inhibiting antibody) of over 1:5
114 coding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neuraminidase (HN) protein, a test
115 ion of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neuraminidase (HN), blocking recept
116 esponse most reliably by comparing bPIV3 and hPIV3 HI titers, and that bPIV3 vaccine prevents vaccine
117 nd could down-regulate surface expression of HPIV3 HN and heterologous HN/H proteins from simian viru
119 ggest that the two receptor binding sites on HPIV3 HN each contribute in distinct ways to virus-cell
121 eV-HPIV3(F-HN) were constructed in which the HPIV3 HN open reading frame and an additional gene junct
123 d to result, in part, from an early block to HPIV3 HN synthesis, as well as an instability of the het
124 V HN-receptor binding is less sensitive than HPIV3 HN-receptor binding to 4-GU-DANA, while its neuram
127 mples from 3 patients with hospital-acquired HPIV3 identified over a 12-day period on a general medic
128 d by the bPIV3 IgA and HI assays than by the hPIV3 IgA and HI assays, that bPIV3-induced antibody res
129 urthermore, MHC class II was also induced by HPIV3 in cells defective in class II transactivator, an
132 RSV F open reading frame was evaluated in rB/HPIV3 in three forms: (i) pre-F without vector-packaging
136 (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulation of p53 in infected cells
137 antibody response can be differentiated from hPIV3-induced antibody response most reliably by compari
139 trate that human parainfluenza virus type 3 (HPIV3) induces incomplete autophagy by blocking autophag
143 espiratory route to rhesus monkeys--in which HPIV3 infection is mild and asymptomatic--and were evalu
144 the basis of which cumulative proportions of hPIV3 infection were estimated to be 11% at 6 months of
145 the second dose exceeded that observed with HPIV3 infection, even though HPIV3 replicates much more
148 ess than that observed following a wild-type HPIV3 infection; however, the titer following the second
150 of 12 cases of human parainfluenza virus 3 (HPIV3) infection that occurred among 64 allogeneic hemat
153 nd HPIV2 are best known to cause croup while HPIV3 is a common cause of bronchiolitis and pneumonia.
156 Exposure histories and molecular analysis of HPIV3 isolates suggested that both community acquired an
160 he gene-end (GE) transcription signal of the HPIV3 matrix (M) protein gene is identical to those of t
161 ah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mumps virus (MuV), and resp
162 neuraminidase activity impacts the extent of HPIV3-mediated fusion by releasing HN from contact with
164 res luciferase reporter gene expression from HPIV3 minigenomes by viral proteins in a recombinant vac
165 ases 13 to 28 resulted in markedly decreased HPIV3 minireplicon replication, indicating these bases c
166 were critical in promoting replication of an HPIV3 minireplicon, while the intergenic sequence and N
167 orted that human parainfluenza virus type 3 (HPIV3) multiplication was inhibited by IFN-alpha in huma
169 lowering the pH (to approach the optimum for HPIV3 neuraminidase) decreased F triggering via release
171 of either human parainfluenza virus type 3 (HPIV3) or Nipah virus receptor binding proteins indicate
172 ein open reading frame (ORF) in place of the HPIV3 ORF, was modified to encode the measles virus hema
174 alyzed the human parainfluenza virus type 3 (HPIV3) P protein and deletion mutants thereof in an in v
176 s resulted in RSV F being packaged in the rB/HPIV3 particle with an efficiency similar to that of RSV
177 y pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope protein hemagglutinin-neuram
178 One bifunctional site (site I) on the HN of HPIV3 possesses both receptor binding and neuraminidase
180 IV3 in primates, we produced viable chimeric HPIV3 recombinants containing the nucleoprotein (N) open
182 t observed with HPIV3 infection, even though HPIV3 replicates much more efficiently than NDV in these
183 parainfluenza virus types 1 and 3 (hPIV1 and hPIV3, respectively) to the glycan array of the Consorti
184 ivo and were found to be associated with the HPIV3 ribonucleoprotein complex in the infected cells.
186 V-neutralizing antibody titers induced by rB/HPIV3-RSV chimeric viruses were equivalent to those indu
187 version of the previously well-tolerated rB/HPIV3-RSV F vaccine candidate that induces a superior RS
188 induced by infection with wild-type RSV, and HPIV3-specific antibody responses were similar to, or sl
189 nsisting of a chimeric bovine/human PIV3 (rB/HPIV3) strain expressing the RSV fusion (F) protein was
191 nduction of MHC class I and II expression by HPIV3 suggests that it plays a role in the infection-rel
192 a level of protection against challenge with HPIV3 that was indistinguishable from that induced by pr
193 version of human parainfluenza virus type 3 (HPIV3) that is attenuated due to the presence of the bov
198 r to those induced by RSV infection and anti-HPIV3 titers similar to those induced by HPIV3 infection
199 V3 vector expressing RSV F as a bivalent RSV/HPIV3 vaccine and have been evaluating means to increase
201 yxoviruses: (i) HPIV3cp45, a live-attenuated HPIV3 vaccine candidate containing multiple attenuating
202 improved version of this well-tolerated RSV/HPIV3 vaccine candidate, with potently improved immunoge
203 e the antibody response to a live attenuated HPIV3 vaccine without affecting viral replication and at
204 gative children as a bivalent intranasal RSV/HPIV3 vaccine, and it was well tolerated but insufficien
206 plications for the design of live attenuated HPIV3 vaccines; specifically, the antibody response agai
209 sion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations in HN were studied.
214 bovine/human parainfluenza type 3 virus (rB/HPIV3) vector expressing the respiratory syncytial virus
215 d chimeric recombinant bovine/human PIV3 (rB/HPIV3) vector expressing the RSV fusion (F) glycoprotein
217 ability, we constructed and characterized rB/HPIV3 viruses expressing RSV F from the first (pre-N), s
218 est this hypothesis, two similar recombinant HPIV3 viruses from which this insert in the M-GE signal
219 nce of p53, the replication of both EMCV and HPIV3 was retarded, whereas, conversely, VSV replication
221 s clinical trial in virus-naive children, rB/HPIV3 was well tolerated but the immunogenicity of wild-
222 bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed previously as a vector expressing R
223 ecombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural
226 positive for HPIV2, and 9 of 10 positive for HPIV3) were positive and were correctly typed by both as
227 nize by the intranasal route against RSV and HPIV3, which are the first and second most important vir
228 ncing coverage to yield the whole genome for HPIV3, while 10 (2 cases and 8 controls) of 13 samples g
229 In contrast, coexpression of F-KDEL with HPIV3 wild-type F or the heterologous receptor-binding p
230 ading frame (ORF) of a recombinant wild-type HPIV3 with the analogous ORF from BPIV3, with the caveat
231 s thus combine the antigenic determinants of HPIV3 with the host range restriction and attenuation ph
232 us immune response to both measles virus and HPIV3, with serum antibody titers to both measles virus
233 -gamma could elicit antiviral effect against HPIV3 without cross talk with the IFN-alpha-signaling pa
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。